Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,101 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,794 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02936089 | Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+ | completed | N/A | 207 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Aug 8, 2023 | clinicaltrials |
| NCT00516828 | Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 21 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03267186 | Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant | completed | Phase 2 | 8 | Andrew RezvaniOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT01772420 | Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia | completed | Phase 2 | 52 | Albert Einstein College of MedicineOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT03435848 | Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy(ELPIS) | completed | Phase 2 | 66 | BioSight Ltd.INDUSTRY | 2 | Jul 27, 2023 | clinicaltrials |
| NCT01816256 | Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms | completed | N/A | 102 | University Health Network, TorontoOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT02575963 | Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients | completed | Phase 1 / Phase 2 | 40 | Actinium PharmaceuticalsINDUSTRY | 2 | Jul 20, 2023 | clinicaltrials |
| NCT02847130 | Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology | completed | — | 530 | Children's Oncology GroupNETWORK | 2 | Jul 19, 2023 | clinicaltrials |
| NCT03050216 | QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML | completed | Phase 2 | 8 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT02311998 | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | completed | Phase 1 / Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT03566446 | CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms | completed | Phase 1 | 10 | Inge Marie SvaneOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT04051307 | Dual Vaccine Trial in Myeloproliferative Neoplasms | completed | Phase 1 / Phase 2 | 9 | Inge Marie SvaneOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT02842827 | A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) | completed | Phase 1 / Phase 2 | 45 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT00046930 | Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia | completed | Phase 3 | 449 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jul 5, 2023 | clinicaltrials |
| NCT02728050 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 84 | University of WashingtonOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT01572662 | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | completed | Phase 2 | 201 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00045305 | Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes | completed | Phase 2 | 17 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04562792 | Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia | completed | Phase 2 | 1 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03719534 | Haplo HCT vs Haplo-cord HCT for Patients With AML | completed | Phase 3 | 134 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT01593254 | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib(DASCERN) | completed | Phase 2 | 262 | Bristol-Myers SquibbINDUSTRY | 15 | Jun 22, 2023 | clinicaltrials |
| NCT02124746 | Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia | completed | Phase 2 | 87 | Sierra Oncology LLC - a GSK companyINDUSTRY | 5 | Jun 18, 2023 | clinicaltrials |
| NCT02141828 | A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene | completed | Phase 1 | 18 | Epizyme, Inc.INDUSTRY | 2 | Jun 18, 2023 | clinicaltrials |
| NCT00641030 | Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes | completed | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02299518 | Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 23 | Alice MimsOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05188326 | Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients | completed | Phase 3 | 54 | Associazione Qol-oneOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05893836 | Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia | completed | — | 555 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 8, 2023 | clinicaltrials |
| NCT02098161 | LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT04484532 | Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers | completed | Early Phase 1 | 130 | Roswell Park Cancer InstituteOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT01141959 | Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients | completed | — | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT01806571 | Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05218902 | A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)(DIM Vidaza) | completed | — | 290 | Bristol-Myers SquibbINDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT03417154 | Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS | completed | Phase 2 | 12 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT01611116 | Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia(TOR-AML) | completed | Phase 2 | 33 | Goethe UniversityOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT04146038 | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | completed | Phase 2 | 5 | Rutgers, The State University of New JerseyOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT05193448 | A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE(ELEGANCE) | completed | — | 177 | French Innovative Leukemia OrganisationOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT03236857 | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | completed | Phase 1 | 143 | AbbVieINDUSTRY | 8 | May 22, 2023 | clinicaltrials |
| NCT00413439 | Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy | completed | Phase 2 / Phase 3 | 18 | Basilea PharmaceuticaINDUSTRY | 1 | May 10, 2023 | clinicaltrials |
| NCT01657604 | TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study(TIGER) | completed | Phase 3 | 717 | University of JenaOTHER | 3 | May 10, 2023 | clinicaltrials |
| NCT02890784 | Dasatinib Holiday for Improved Tolerability(DasaHIT) | completed | Phase 3 | 291 | University of JenaOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT03860376 | Ex Vivo Drug Sensitivity Testing and Mutation Profiling | completed | — | 25 | Florida International UniversityOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05455268 | Information Support Using an Online Learning Platform for Malaysian Pediatric Leukemia and Lymphoma Parents(eHOPE) | completed | N/A | 51 | Universiti Kebangsaan Malaysia Medical CentreOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT04644419 | Chemotherapy-related Cognitive Impairment and Acute Leukemia | completed | — | 25 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT01925131 | S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 | 50 | SWOG Cancer Research NetworkNETWORK | 1 | May 3, 2023 | clinicaltrials |
| NCT04282343 | DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer | completed | N/A | 25 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT02581007 | Reduced Intensity Conditioning Transplant Using Haploidentical Donors | completed | Phase 2 | 25 | Northside Hospital, Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05825326 | Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador | completed | — | 40 | Sociedad de Lucha Contra el Cáncer del EcuadorOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT03349502 | MG4101 for Refractory or Relapsed AML | completed | Phase 2 | 11 | Seoul National University HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT02891278 | Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML | completed | Phase 1 | 6 | Columbia UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT02662933 | Investigating the Relationship Between Physical Function, Comorbidity and Cytogenetic Risk Group in Older Adults With Acute Myelogenous Leukemia (AML) | completed | N/A | 82 | Wake Forest University Health SciencesOTHER | 0 | Apr 10, 2023 | clinicaltrials |
| NCT05611216 | Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation | completed | — | 164 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Aug 8, 2023source: clinicaltrials